Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It also has designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Generation 3 or Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
äŒæ¥ã³ãŒãNXLIW
äŒç€ŸåNexalin Technology Inc
äžå Žæ¥Sep 16, 2022
æé«çµå¶è²¬ä»»è
ãCEOãMr. Mark White
åŸæ¥å¡æ°- -
蚌åžçš®é¡Company Warrant
æ±ºç®ææ«- -
æ¬ç€Ÿæåšå°1776 Yorktown
éœåžHOUSTON
蚌åžååŒæNASDAQ Capital Market Consolidated
åœUnited States of America
éµäŸ¿çªå·77056
é»è©±çªå·18322600222
ãŠã§ããµã€ãhttps://nexalin.com
äŒæ¥ã³ãŒãNXLIW
äžå Žæ¥Sep 16, 2022
æé«çµå¶è²¬ä»»è
ãCEOãMr. Mark White
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã